{
    "clinical_study": {
        "@rank": "82203", 
        "arm_group": [
            {
                "arm_group_label": "Omega-3 Fatty Acids", 
                "arm_group_type": "Experimental", 
                "description": "1g of Omega-3 per day [400mg DHA & 600mg EPA] for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner"
            }, 
            {
                "arm_group_label": "Omega-3 Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1g of Omega-3 Placebo per day for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner"
            }
        ], 
        "brief_summary": {
            "textblock": "The overarching aim of the proposed study is to assess whether omega-3 fatty acids\n      supplementation can augment the effects of methylphenidate in children with ADHD. The\n      investigators hypothesized that omega-3 fatty acids supplementation will be associated with\n      improved ADHD symptoms."
        }, 
        "brief_title": "Omega-3 Fatty Acids Supplementation in ADHD", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "ADHD", 
        "condition_browse": {
            "mesh_term": "Attention Deficit Disorder with Hyperactivity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Participants between ages 6 and 12 years who:\n\n          1. have been clinically diagnosed with ADHD by a physician\n\n          2. meet the criteria of ADHD-Inattention, ADHD-Hyperactivity-Impulsivity, or\n             ADHD-Combined type as determined by the SNAP-IV (Swanson, 1992)\n\n          3. are willing to participate in a randomized, double-blind, placebo-controlled trial,\n             complete with written, informed parental consent,\n\n          4. are on stable dosage of methylphenidate treatment before the start of the study\n\n          5. are able to speak English or German\n\n        Exclusion Criteria:\n\n          1. Participants who are younger than 6 years old or older than 12 years old\n\n          2. Those who have not been clinically diagnosed with ADHD by a physician\n\n          3. Those who did not meet the criteria of ADHD-Inattention,\n             ADHD-Hyperactivity-Impulsivity, or ADHD-Combined type as determined by the SNAP-IV\n             (Swanson, 1992)\n\n          4. Those without written parental consent\n\n          5. Those with brain pathology such as serious head injury, epilepsy, and intellectual\n             disability (IQ < 70)\n\n          6. Those with titrated dosage of methylphenidate before the start of the study\n\n          7. Those on neurofeedback training, and/or psychosocial intervention addressing\n             attention problems\n\n          8. Those with known hypersensitivity to the IMP under investigation\n\n          9. Those who are unable to read and understand the parent/participant information\n\n         10. Those receiving medications other than methylphenidate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777048", 
            "org_study_id": "203/12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Omega-3 Fatty Acids", 
                "intervention_name": "Omega-3 Fatty Acids Supplementation", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Omega-3 Placebo", 
                "description": "Placebo capsules manufactured to mimic Omega-3 capsules", 
                "intervention_name": "Omega-3 Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Basel", 
                    "country": "Switzerland", 
                    "zip": "4058"
                }, 
                "name": "Universit\u00e4re Psychiatrische Kliniken (UPK) Basel"
            }, 
            "investigator": [
                {
                    "last_name": "Oliver Pick, Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Klaus Schmeck, Dr. med Dip.-Psych.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jens Gaab, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Augmenting the Effects of Methylphenidate: A Randomized, Placebo-Controlled Trial of Omega-3 Fatty Acids Supplementation in Children With Attention Deficit Hyperactivity Disorder", 
        "overall_contact": {
            "email": "sibylle.meier@stud.unibas.ch", 
            "last_name": "Sibylle Meier"
        }, 
        "overall_official": {
            "affiliation": "University of Basel", 
            "last_name": "Yoon Phaik Ooi, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Switzerland: Ethikkommission", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in ADHD Rating Scale-IV total score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 6, and Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777048"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Basel, Switzerland", 
            "investigator_full_name": "Yoon Phaik Ooi", 
            "investigator_title": "Researcher", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Change in Child Behaviour Checklist total score", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 12"
        }, 
        "source": "University Hospital, Basel, Switzerland", 
        "sponsors": {
            "collaborator": {
                "agency": "Universit\u00e4re Psychiatrische Kliniken (UPK) Basel", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University Hospital, Basel, Switzerland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}